Karen Lu, MD

Gynecological oncology

Associations

• Gynecologic Oncology
• Health Outcomes & Behavior Program

Gynecological oncology

• Cobb LP, Dai Y, Molina Ayala M, Ozirmak Lermi N, Hernandez SD, Davis J, Lee S, Lawson BC, Hajek RA, Celestino J, Liu J, Wang L, Soto LMS, Haymaker C, Chen K, Jiang M, Lu W, Sanchez-Espiridion B, Dang M, Hull S, Vining D, Fellman B, Yuan Y, Sood AK, Westin SN, Taylor J, Bevers M, Shafer A, Fleming ND, Lu KH, Gershenson DM, Jazaeri AA. A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. Nat Commun. 2026 Jun.17(1). Pubmedid: 42374029. Pmcid: PMC13457953.
• Hoffman M, Chi D, Cliby W, Lu KH, Fan W, Clarke-Pearson D. National Trends in Radical Hysterectomy at Gynecologic Oncology Fellowship Training Programs. O G Open. 2026 Jun.3(3):e175. Pubmedid: 42220418. Pmcid: PMC13221115.
• Adjei NN, Yeh PG, Haas A, Sun CC, Zhao H, Stone R, Roche KL, Lu KH, Toumazis I, Meyer LA. Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis. Int J Gynecol Cancer. 2026 Jun.36(6):102884. Pubmedid: 41605705.
• Gootzen TA, Norquist BM, Wilke RN, Hoppenreijs B, van Gelder MM, Kets CM, Simons M, Lu KH, Swisher EM, Hermens RP, Steenbeek MP, de Hullu JA. International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study. Am J Obstet Gynecol. 2026 Jun. Pubmedid: 42323120.
• Hoffman M, Clarke-Pearson D, Chi D, Lu KH, Fan W, Cliby W. Recent national trends in pelvic and paraaortic lymphadenectomy in gynecologic oncology fellowship training programs: ACGME data from 2019-2025. Gynecol Oncol Rep. 2026 Jun.65:102088. Pubmedid: 42064030. Pmcid: PMC13125898.
• Lu KH, Norquist BM, Chisholm GB, Peterson CB, Long Roche KC, Bakkum-Gamez JN, Romero IL, Feltmate C, Levine DA, Kim S, Hagemann AR, Carter J, Hickey M, Crase J, Gavin K, Polinsky D, D'Andrea AD, Nebgen DR, Swisher EM. Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2026 Jul.9(7):e2622026. Pubmedid: 42412428.
• Mills AM, Euscher ED, McCluggage WG, Mirkovic J, Park KJ, Kolin DL, Hoang L, Kim HS, How JA, Lu KH, Ring KL, Howitt BE. Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium. Int J Gynecol Pathol. 2026 Jan.45(1):57-78. Pubmedid: 41289365. Pmcid: PMC12704686.
• Aoun E, Lawson B, Awujo C, Nebgen D, Soletsky BR, Chisholm GB, Lu KH, Nitecki Wilke R. Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery. Int J Gynecol Cancer. 2026 Feb.36(2):101870. Pubmedid: 39496390. Pmcid: PMC12228828.
• Jorgensen KA, Agusti N, Coffin T, Barajas K, Iniesta MD, Bednar EM, Kanbergs A, Wilke RN, Beshar I, Pirzadeh-Miller S, Lahiri S, Pratt K, Jennings K, Bosch H, Leath CA, Karlan B, Frey M, Sharaf R, Lu K, Rauh-Hain JA. A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial. JAMA Netw Open. 2026 Aug.9(8):e2630668. Pubmedid: 42658496. Pmcid: PMC13522964.
• Wilke RN, Pennington KP, Gootzen TA, Steenbeek MP, de Hullu JA, Long KC, Blank SV, Swisher EM, Lu KH, Norquist B. Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution. Am J Obstet Gynecol. 2026 Apr.234(4):1003-1006. Pubmedid: 41183726.
• Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clin Cancer Res. 2025 Oct.31(19):4122-4135. Pubmedid: 40748258. Pmcid: PMC12485385.
• Wilke RN, Liu J, Westin SN, Fellman BM, Sims TT, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. Int J Gynecol Cancer. 2025 Nov.35(11):101865. Pubmedid: 39414313. Pmcid: PMC12236096.
• Huang M, McCourt C, Powell MA, Lu KH. Amplifying SGO'S voice: The impact of the Society of Gynecologic Oncology (SGO) clinical practice committee publications in Gynecologic Oncology. Gynecol Oncol. 2025 Nov.202:A1-A2. Pubmedid: 41352958.
• Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res (Phila). 2025 May.18(5):299-306. Pubmedid: 39930864.
• Ring KL, Mills AM, Howitt BE, Grisham RN, Euscher ED, Kim HS, Klopp AH, Kolin DL, McCluggage WG, Mirkovic J, Park KJ, Aoun E, Awujo C, Son J, Mok SC, Ferri-Borgogno S, Hong DS, Hoang L, Jazaeri AA, How JA, Lu KH. Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics. Gynecol Oncol. 2025 Jun.197:57-65. Pubmedid: 40279981.
• Bowen MB, Melendez B, Zhang Q, Moreno D, Peralta L, Chan WK, Jeter C, Tan L, Zal MA, Lorenzi PL, Dunner K, Yang RK, Broaddus RR, Celestino J, Gokul N, Whitley E, Scoville DM, Kim TH, Jeong JW, Schmandt R, Lu K, Kim HE, Yates MS. Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer. JCI Insight. 2025 Feb.10(6). Pubmedid: 39964762. Pmcid: PMC11949016.
• Gootzen TA, Steenbeek MP, van Gelder MMHJ, van Bommel MHD, Timmer-Bonte JNH, Kets CM, Wilke RN, Swisher EM, Norquist BM, Lu KH, Hermens RPMG, de Hullu JA. Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study. Am J Obstet Gynecol. 2025 Dec.233(6):638.e1-638.e13. Pubmedid: 40532962.
• Corvigno S, Yao J, Asare A, Zhao L, Celestino J, Hajek RA, Goette EAA, Rogers RT, Montoya RN, Song P, Zhang QC, Song X, Mohammad MM, Shaw KR, Zhang J, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Front Oncol. 2025 Apr.15:1538446. Pubmedid: 40365343. Pmcid: PMC12069037.
• Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer. 2024 Nov.24(11):792-809. Pubmedid: 39354069.
• How JA, Jazaeri AA, Westin SN, Lawson BC, Klopp AH, Soliman PT, Lu KH. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov.21(11):781-800. Pubmedid: 39198622. Pmcid: PMC12084113.
• Ishizawa S, Niu J, Tammemagi MC, Irajizad E, Shen Y, Lu KH, Meyer LA, Toumazis I. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J Natl Cancer Inst. 2024 Nov.116(11):1798-1806. Pubmedid: 39038822.
• Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov.30(22):5073-5082. Pubmedid: 38922360. Pmcid: PMC11567806.
• Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May.27(5):109801. Pubmedid: 38726365. Pmcid: PMC11079458.
• Young Han C, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Brit J Cancer. 2024 Mar.130(5):861-868. Pubmedid: 38195887. Pmcid: PMC10912308.
• Wilke RN, Bednar EM, Pirzadeh-Miller S, Lahiri S, Scarinci IC, Leath Iii CA, Frey MK, Lu KH, Rauh-Hain JA. Cascade genetic testing: an underutilized pathway to equitable cancer care?. Familial Cancer. 2024 Jun.23(2):141-145. Pubmedid: 38748383. Pmcid: PMC11751770.
• Suidan RS, Sun CC, Schneider AK, Lu KH, Giordano SH, Meyer LA. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 Jun.185:101-107. Pubmedid: 38377761. Pmcid: PMC12558048.
• Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul.30(14):2986-2995. Pubmedid: 38687597. Pmcid: PMC11250057.
• Bednar EM, Rauh-Hain JA, Garcia JJ, de Aguinaga N, Powell MA, Peral SL, Nitecki R, Jorgensen K, Rudy NL, Lu KH, Leath CA, Scarinci IC. Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations-A Qualitative Study. Cancer Prev Res (Phila). 2024 Jan.17(1):19-28. Pubmedid: 37913800. Pmcid: PMC10872900.
• Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb.12(2). Pubmedid: 38309721. Pmcid: PMC10840042.
• Ferri-Borgogno S, Burks JK, Seeley EH, McKee TD, Stolley DL, Basi AV, Gomez JA, Gamal BT, Ayyadhury S, Lawson BC, Yates MS, Birrer MJ, Lu KH, Mok SC. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers (Basel). 2024 Feb.16(5). Pubmedid: 38473208. Pmcid: PMC10930466.
• Bednar EM, Nitecki Wilke R, Jorgensen K, Walsh MT, Nutt S, Lu KH, Nóbrega L, De Souza APSD, da Silva Oliveira G, da Cunha Andrade CEM, Purizaca-Rosillo N, Mora P, López Blanco A, Gallardo-Alvarado LN, Cantú-de León D, Rauh-Hain JA. Feasibility of an environmental scan-based approach to collecting information about factors impacting cancer genetics services in Latin American countries. J Community Genet. 2024 Dec.15(6):681-686. Pubmedid: 39397225. Pmcid: PMC11645378.
• Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 Apr.130(7):1061-1071. Pubmedid: 38009662. Pmcid: PMC11267492.
• Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol. 2024 Apr.42(10):1102-1109. Pubmedid: 38194613. Pmcid: PMC11003507.
• Cui W, Rocconi RP, Thota R, Anderson RA, Bruinooge SS, Comstock IA, Denduluri N, Gassman A, Gralow J, Hutt KJ, Amiri-Kordestani L, Lambertini M, Leighton J, Lu KH, Mostoufi-Moab S, Pollastro T, Pradhan S, Saber H, Schenkel C, Spratt D, Wedam S, Phillips KA. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement. Lancet Oncol. 2023 Oct.24(10):e415-e423. Pubmedid: 37797647.
• Swisher EM, Rayes N, Bowen D, Peterson CB, Norquist BM, Coffin T, Gavin K, Polinsky D, Crase J, Bakkum-Gamez JN, Blank SV, Munsell MF, Nebgen D, Fleming GF, Olopade OI, Law S, Zhou A, Levine DA, D'Andrea A, Lu KH. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov.9(11):1547-1555. Pubmedid: 37707822. Pmcid: PMC10502696.
• Kahn RM, Gordhandas S, Godwin K, Stone RL, Worley MJ, Lu KH, Long Roche KC. Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review. JAMA Surg. 2023 Nov.158(11):1204-1211. Pubmedid: 37672283. Pmcid: PMC11185162.
• Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Brit J Haematol. 2023 May.201(3):e25-e29. Pubmedid: 36951293.
• Bednar EM, Chen M, Walsh MT, Eppolito AL, Klein MH, Teed K, Hodge B, Hunter J, Chao HG, Davis D, Serchion W, Yobbi C, Krukenberg R, Jenkinson SB, Moore JJ, Garcia C, Gonzalez F, Murray T, Nielsen LD, Ho B, Haas M, Greenzweig SB, Anderson A, Johnson C, Morman NA, Bowdish E, Wise E, Cooper JN, Russ PK, Tondo-Steele K, de Gracia BF, Levin B, Mattie K, Zarnawski K, Kalasinski M, Stone J, O'Brien C, Bream A, Kennedy AM, Paul RA, Bilbao M, Romero M, Carr RL, Siettmann JM, Vercruyssen AK, Leon K, Arun BK, Grainger AV, Warshal DP, Bowman E, Goedde TA, Halaharvi D, Rath K, Grana G, Mina L, Lu KH. Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems. Gynecol Oncol. 2023 May.172:106-114. Pubmedid: 37004303. Pmcid: PMC10192022.
• Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 Mar.41(9):1725-1734. Pubmedid: 36469840. Pmcid: PMC10489509.
• Zhukovsky DS, Soliman P, Liu D, Meyer M, Haider A, Heung Y, Gaeta S, Lu K, Stepan K, Stanton P, Rodriguez A, Bruera E. Patient Engagement With Early Stage Advance Care Planning at a Comprehensive Cancer Center. Oncologist. 2023 Jun.28(6):542-550. Pubmedid: 36848260. Pmcid: PMC10243763.
• Steenbeek MP, van Bommel MHD, intHout J, Peterson CB, Simons M, Roes KCB, Kets M, Norquist BM, Swisher EM, Hermens RPMG, Lu KH, de Hullu JA. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Int J Gynecol Cancer. 2023 Jun.33(6):982-987. Pubmedid: 37045546. Pmcid: PMC10314019.
• Yoshida-Court K, Karpinets TV, Mitra A, Solley TN, Dorta-Estremera S, Sims TT, Delgado Medrano AY, El Alam MB, Ahmed-Kaddar M, Lynn EJ, Sastry KJ, Zhang J, Futreal A, Nick A, Lu K, Colbert LE, Klopp AH. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. PLoS One. 2023 Jan.18(1):e0279590. Pubmedid: 36607962. Pmcid: PMC9821423.
• Bednar EM, Harper B, Walsh MT, Rechis R, Bilbao M, Carr RL, Eppolito AL, Goedde T, Levin B, Mattie K, Morman NA, Rath K, Russ P, Siettmann JM, Warshal D, Wise E, Yobbi C, Lu KH. Implementation and outcome evaluations of a multi-site improvement program in cancer genetics. J Genet Couns. 2023 Feb.32(1):182-196. Pubmedid: 36117454.
• Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, Fahrmann JF. A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. Clin Cancer Res. 2022 Nov.28(21):4669-4676. Pubmedid: 36037307. Pmcid: PMC9633421.
• Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Mats ...
• Corrigan KL, Yoder A, De B, Lin L, Jhingran A, Joyner MM, Eifel PJ, Colbert LE, Lu KH, Klopp AH. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol. 2022 Mar.164(3):550-557. Pubmedid: 34974906. Pmcid: PMC9257896.
• Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Mats ...
• Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, de Hullu JA. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022 Jun.40(17):1879-1891. Pubmedid: 35302882. Pmcid: PMC9851686.
• Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers (Basel). 2022 Jun.14(13). Pubmedid: 35804849. Pmcid: PMC9264950.
• Yeh LT, Lin CW, Lu KH, Hsieh YH, Yeh CB, Yang SF, Yang JS. Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway. Int J Mol Sci. 2022 Jan.23(1). Pubmedid: 35008910. Pmcid: PMC8745393.
• Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK. Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. Contemp Clin Trials. 2022 Feb.113:106662. Pubmedid: 34971795.
• Dholakia J, Lee YW, Lu KH, Huh WK, Yamada SD, Fuh KC, Kumar AS, Liang MI, Nair N, Kim KH. Identity-related experiences of Asian American trainees in gynecologic oncology. Gynecol Oncol Rep. 2022 Dec.44:101097. Pubmedid: 36388752. Pmcid: PMC9664478.
• Sidey-Gibbons CJ, Sun C, Schneider A, Lu SC, Lu K, Wright A, Meyer L. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep. 2022 Dec.12(1):21269. Pubmedid: 36481644. Pmcid: PMC9732183.
• Wamsley C, Kislevitz M, Vingan NR, Oesch S, Lu K, Barillas J, Hoopman J, Akgul Y, Basci D, Kho K, Zimmern PE, Kenkel JM. A Randomized, Placebo-Controlled Trial Evaluating the Single and Combined Efficacy of Radiofrequency and Hybrid Fractional Laser for Nonsurgical Aesthetic Genital Procedures in Post-Menopausal Women. Aesthet Surg J. 2022 Dec.42(12):1445-1459. Pubmedid: 35882474.
• Zhang L, Au-Yeung CL, Huang C, Yeung TL, Ferri-Borgogno S, Lawson BC, Kwan SY, Yin Z, Wong ST, Thomas V, Lu KH, Yip KP, Sham JSK, Mok SC. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. J Exp Clin Cancer Res. 2022 Aug.41(1):242. Pubmedid: 35953818. Pmcid: PMC9373370.
• Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, Lu KH, Mikos AG, Yates MS. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release. 2021 Nov.339:521-530. Pubmedid: 34648891. Pmcid: PMC8650567.
• Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK. Facilitated cascade testing (FaCT): a randomized controlled trial. Int J Gynecol Cancer. 2021 May.31(5):779-783. Pubmedid: 33443030. Pmcid: PMC8603783.
• Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Borthwick MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol. 2021 Mar.224(3):278.e1-278.e14. Pubmedid: 32835719. Pmcid: PMC7897335.
• Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 Mar.160(3):777-785. Pubmedid: 33563487. Pmcid: PMC8538374.
• Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021 Jun.161(3):660-667. Pubmedid: 33867146. Pmcid: PMC8165031.
• Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 Jun.161(3):653-659. Pubmedid: 33736856. Pmcid: PMC8164998.
• How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 Jul.162(1):24-31. Pubmedid: 33958211. Pmcid: PMC8222164.
• Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 Jul.225(1):68.e1-68.e11. Pubmedid: 33549538. Pmcid: PMC8254740.
• Huepenbecker S, Hillman RT, Iniesta MD, Chen T, Cain K, Mena G, Lasala J, Wang XS, Williams L, Taylor JS, Lu KH, Ramirez PT, Meyer LA. Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery. Int J Gynecol Cancer. 2021 Jul.31(7):1052-1060. Pubmedid: 34135073. Pmcid: PMC8328052.
• Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 Jul.162(1):65-71. Pubmedid: 33838925. Pmcid: PMC8287765.
• Glubb DM, Thompson DJ, Aben KK, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Bützow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, DeFazio A, Doherty JA, Dork T, du Bois A, Dunning AM, Durst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM ...
• Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 Feb.224(2):191.e1-191.e15. Pubmedid: 32805208. Pmcid: PMC7855308.
• Lu KH, Broaddus RR. Endometrial Cancer. Reply. N Engl J Med. 2021 Feb.384(6):586. Pubmedid: 33567204.
• Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671595. Pmcid: PMC7927060.
• How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Feb.13(5). Pubmedid: 33668244. Pmcid: PMC7956737.
• Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 Dec.27(23):6354-6365. Pubmedid: 34518313. Pmcid: PMC8639651.
• Mitra A, Yoshida-Court K, Solley TN, Mikkelson M, Yeung CLA, Nick A, Lu K, Klopp AH. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells. Sci Rep. 2021 Apr.11(1):9149. Pubmedid: 33911091. Pmcid: PMC8080718.
• Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 Apr.161(1):56-62. Pubmedid: 33536126. Pmcid: PMC8247119.
• Lu KH, Broaddus RR. Endometrial Cancer. N Engl J Med. 2020 Nov.383(21):2053-2064. Pubmedid: 33207095.
• Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 Nov.30(11):1733-1737. Pubmedid: 33020204.
• McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 Mar.37(3):371-386.e12. Pubmedid: 32109374. Pmcid: PMC7337255.
• Zhang L, Kwan SY, Wong KK, Solaman PT, Lu KH, Mok SC. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel). 2020 Mar.12(3). Pubmedid: 32183290. Pmcid: PMC7140057.
• Cun HT, Lu KH. Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy. Obstet Gynecol. 2020 Mar.135(3):495-497. Pubmedid: 32028509.
• Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, Wong STC, Nagrath D, Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun. 2020 Jul.11(1):3546. Pubmedid: 32669559. Pmcid: PMC7363861.
• Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC, Jacobs IJ, Zaikin A, Menon U. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers (Basel). 2020 Jul.12(7). Pubmedid: 32708856. Pmcid: PMC7409061.
• Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, Lu KH. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel). 2020 Jan.12(1). Pubmedid: 31906456. Pmcid: PMC7016780.
• Donato KM, Moore K, Parker WM, Peterson SK, Gritz ER, Amos CI, Lu KH, Lynch PM, Rodriguez-Bigas MA, You YN, Burton-Chase AM. Health and lifestyle behaviors in colorectal cancer survivors with and without Lynch syndrome. J Community Genet. 2020 Jan.11(1):59-63. Pubmedid: 31016603. Pmcid: PMC6962402.
• Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 Feb.30(2):187-192. Pubmedid: 31843871. Pmcid: PMC7307445.
• Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 Feb.26(3):581-587. Pubmedid: 31628143. Pmcid: PMC7002216.
• Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel). 2020 Feb.12(2). Pubmedid: 32092936. Pmcid: PMC7072578.
• Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. J Natl Cancer Inst. 2020 Dec.112(12):1190-1203. Pubmedid: 32413141. Pmcid: PMC7735770.
• Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 Dec.29(12):2504-2512. Pubmedid: 33051337. Pmcid: PMC7710577.
• Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 Aug.30(8):1195-1202. Pubmedid: 32616627. Pmcid: PMC8328049.
• Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel). 2020 Aug.12(9). Pubmedid: 32867127. Pmcid: PMC7563948.
• Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 Apr.31(2):107502. Pubmedid: 32294438. Pmcid: PMC7234854.
• Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr. 2020 Apr.4(2):pkaa002. Pubmedid: 32211581. Pmcid: PMC7083268.
• Onstad M, Ducie J, Fellman BM, Abu-Rustum NR, Leitao M, Mariani A, Multinu F, Lu KH, Soliman P. Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2020 Apr.30(4):485-490. Pubmedid: 31980487. Pmcid: PMC8270113.
• Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 Apr.38(11):1222-1245. Pubmedid: 31986064. Pmcid: PMC8842911.
• Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, Lu KH, Basen-Engquist K. Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review. Hered Cancer Clin Pract. 2020.18:5. Pubmedid: 32165993. Pmcid: PMC7060535.
• Creutzberg CL, Lu KH, Fleming GF. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. J Clin Oncol. 2019 Sep.37(27):2490-2500. Pubmedid: 31403860.
• Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Pande M, Vilar E, You YN, Rodriguez-Bigas MA, Strong LL, Lynch PM, Lu KH, Basen-Engquist K. Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review. Familial Cancer. 2019 Oct.18(4):399-420. Pubmedid: 31236808. Pmcid: PMC6863045.
• Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 Oct.125(19):3347-3353. Pubmedid: 31225906. Pmcid: PMC6744337.
• Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Collaborators GS, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 Oct.40(10):1781-1796. Pubmedid: 31112363. Pmcid: PMC6764847.
• Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer. 2019 Nov.126(4):725-736. Pubmedid: 31714597. Pmcid: PMC6992519.
• Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 Mar.152(3):439-444. Pubmedid: 30876486. Pmcid: PMC6662191.
• Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila). 2019 Mar.12(3):171-184. Pubmedid: 30709840. Pmcid: PMC6410372.
• Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 Mar.152(3):501-508. Pubmedid: 30876495. Pmcid: PMC6422048.
• Sun CC, Meyer LA, Daniels MS, Bodurka DC, Nebgen DR, Burton-Chase AM, Lu KH, Peterson SK. Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 Mar.152(3):514-521. Pubmedid: 30876497. Pmcid: PMC6422049.
• Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prev Res (Phila). 2019 Jun.12(6):391-400. Pubmedid: 30967390. Pmcid: PMC6548633.
• Nebgen DR, Lu KH, Bast RC. Novel Approaches to Ovarian Cancer Screening. Curr Oncol Rep. 2019 Jul.21(8):75. Pubmedid: 31346778. Pmcid: PMC6662655.
• Kurnit KC, Lu KH, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract. 2019 Jul.15(7):383-384. Pubmedid: 31283416. Pmcid: PMC6881185.
• Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, Lu KH. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing. BMC Cancer. 2019 Jul.19(1):648. Pubmedid: 31266460. Pmcid: PMC6604336.
• Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 Jul.154(1):22-28. Pubmedid: 31109659. Pmcid: PMC7523189.
• Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 Jan.152(1):31-37. Pubmedid: 30414738. Pmcid: PMC6321768.
• Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 Feb.152(2):328-333. Pubmedid: 30528888. Pmcid: PMC6358478.
• Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 Aug.221(2):136.e1-136.e9. Pubmedid: 30965052. Pmcid: PMC7392324.
• Dottino JA, He W, Sun CC, Zhao H, Fu S, Lu KH, Meyer LA. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019 Aug.154(2):405-410. Pubmedid: 31208738. Pmcid: PMC6810571.
• Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. Gynecol Oncol. 2019 Apr.153(1):184-191. Pubmedid: 30711300. Pmcid: PMC6430691.
• Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstet Gynecol. 2019 Apr.133(4):795-802. Pubmedid: 30870286. Pmcid: PMC7181403.
• Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 Sep.132(3):545-554. Pubmedid: 30095787. Pmcid: PMC6105510.
• Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 Nov.151(2):374-380. Pubmedid: 30213435. Pmcid: PMC6235625.
• Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel). 2018 Nov.10(12). Pubmedid: 30469497. Pmcid: PMC6316352.
• Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, Giordano SH, Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 Nov.151(2):269-274. Pubmedid: 30253875. Pmcid: PMC6294439.
• Parchem JG, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y, Lee SB, Gattone VH, Parry S, Strauss JF, Garovic VD, McElrath TF, Lu KH, Sibai BM, LeBleu VS, Carmeliet P, Kalluri R. Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. J Clin Invest. 2018 Nov.128(11):5008-5017. Pubmedid: 30179860. Pmcid: PMC6205389.
• Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A. rs ...